Microgravity drug research is expanding from ISS crystal studies to commercial manufacturing efforts. New experiments and a Varda-United Therapeutics collaboration target improved drug stability, delivery and production.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
New research reveals metformin regulates blood sugar through brain pathways involving the Rap1 protein in the hypothalamus. The study shows suppressing Rap1 in the brain prevents metformin from lowering blood sugar in diabetic mice. These findings could lead to new diabetes treatments targeting this brain pathway.
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
Eli Lilly's orforglipron demonstrated superior A1C reduction and weight loss compared to oral semaglutide in the ACHIEVE-3 trial, with regulatory submissions filed in over 40 countries and a potential US decision expected in Q2 2026.
